Hong Kong AI Medicine R&D Company Insilico Medicine Raised $37 Million in a Series B Round Funding Led by Qiming Venture Capital

Hong Kong AI medicine R&D company Insilico Medicine raised $37 million in a series B round funding led by Qiming Venture Capital, and followed by Eight Roads, F-Prime Capital, LillyAsia Ventures, Sinovation Venture, Baidu Ventures, Orchid Pavilion Investment, BOLD Capital Partners, and other investors. The investment will be used on product launch, recruitment, and product line expansion.

Insilico Medicine provides pharmaceutical companies with cost-saving and effective AI drug R&D solutions. It also provides individuals with AI customized medical platform to help users assess their health and life expectancy.